Evis Bioscience raises €656K Seed round
17 December 2025· Schlieren, Switzerland· biotech, gene_therapy, drug_delivery, nanotechnology, materials, b2b
To develop and commercialize early-stage platforms, expand its therapeutic pipeline, associated services, and licensing initiatives.
About Evis Bioscience
Stage
Seed
Headquarters
Schlieren, Switzerland
Founded
2024
Team Size
6–20
Sectors
biotechgene_therapydrug_deliverynanotechnologymaterialsb2b
Source: https://capitalcell.com/en/campaign/evis-bioscience/